Greenwich lifesciences inc
WebJan 5, 2024 · Greenwich LifeSciences, Inc. 13.21 +0.20 +1.58%: TRENDING. 1. Battery maker Northvolt in talks for over $5 billion in financing -FT. 2. Aging Shadow Fleet Carrying Russian Oil Poses Disaster Risk. 3.
Greenwich lifesciences inc
Did you know?
WebApr 14, 2024 · Greenwich LifeSciences has a 52-week low of $6.82 and a 52-week high of $21.50. The stock’s fifty day simple moving average is $14.92 and its 200-day simple moving average is $13.48. The... WebApr 13, 2024 · Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) VP Jaye Thompson purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, …
WebApr 14, 2024 · On Friday, March 10th, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $12.12 per share, with a total value of $12,120.00. WebSep 6, 2024 · Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data. Greenwich LifeSciences' CEO, Snehal Patel, runs this company almost all by ...
WebApr 10, 2024 · A rating of 81 puts Greenwich Lifesciences Inc ( GLSI) near the top of the Healthcare sector according to InvestorsObserver . Greenwich Lifesciences Inc's score … WebApr 14, 2024 · Greenwich LifeSciences, Inc. has a 12-month low of $6.82 and a 12-month high of $21.50. The firm’s 50-day moving average price is $14.92 and its two-hundred day moving average price is $13.48.
WebApr 6, 2024 · A high-level overview of Greenwich LifeSciences, Inc. (GLSI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
WebApr 11, 2024 · NASDAQ:GLSI opened at $12.65 on Monday. Greenwich LifeSciences has a 52 week low of $6.82 and a 52 week high of $21.50. The stock’s fifty day moving average is $15.24 and its two-hundred day ... chinese food haliburton ontarioWebOct 4, 2024 · Business Wire. Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast … chinese food halswellWebApr 14, 2024 · Greenwich LifeSciences, Inc. has a 1-year low of $6.82 and a 1-year high of $21.50. The stock has a market cap of $153.81 million, a PE ratio of -21.00 and a beta of 0.93. grand itasca clinic mychart loginWebBy proceeding to use this website, you consent to our use of cookies as described in our Privacy Policy.. Close grand italy tourWebApr 14, 2024 · Greenwich LifeSciences, Inc. has a 1-year low of $6.82 and a 1-year high of $21.50. The stock has a market cap of $153.81 million, a PE ratio of -21.00 and a beta of … chinese food hamdenWebGreenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer … Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical … GP2 immunotherapy trains a patient’s T cells to recognize and destroy … The current, ongoing trial is a Phase III clinical trial registered with the name, … Company Profile. Business Description: Greenwich LifeSciences (the … about. management team; board of directors; technology. our gp2 cancer … Dr. Thompson has over 30 years of experience in pharmaceutical and … GP2 is a nine amino acid transmembrane peptide of the HER2/neu protein. … Understand cancer and immunotherapy, cancer’s escape from … Greenwich LifeSciences Provides Year End Update. Dec 1, 2024 6:00am EST. … Company Info - Greenwich LifeSciences, Inc. (GLSI) GP2 grand itasca clinic and hospital labWebSep 29, 2024 · STAFFORD, Texas-- ( BUSINESS WIRE )--Greenwich LifeSciences, Inc. (the “Company”), a clinical-stage biopharmaceutical company focused on the … grand itasca jobs grand rapids mn